Literature DB >> 18794710

Systemic sclerosis in northwestern Spain: a 19-year epidemiologic study.

Maria C Arias-Nuñez1, Javier Llorca, Tomas R Vazquez-Rodriguez, Ines Gomez-Acebo, Jose A Miranda-Filloy, Javier Martin, Carlos Gonzalez-Juanatey, Miguel A Gonzalez-Gay.   

Abstract

To investigate the epidemiology of systemic sclerosis (SSc) in southern Europe, we assessed the incidence, prevalence, clinical spectrum, and survival of patients diagnosed with SSc in the Lugo region of northwestern Spain. Between January 1988 and December 2006, SSc was diagnosed in 78 Lugo residents according to the criteria proposed by LeRoy and Medsger and/or the 1980 American College of Rheumatology (ACR) preliminary criteria for the classification of SSc. However, only 44 (56.4%) of the 78 patients fulfilled the 1980 ACR criteria for the classification of SSc. The mean age at the time of disease diagnosis was 59.8 +/- 13.3 years. Twenty-three (29.5%) met definitions for diffuse SSc (dSSc), and 55 (70.5%) for limited SSc (lSSc). Patients with lSSc had a longer disease duration before the diagnosis (10.2 +/- 12.0 yr) than those with dSSc (3.7 +/- 3.2yr) (p < 0.001). Based on the criteria proposed by LeRoy and Medsger and/or the 1980 ACR criteria for the classification of SSc, the overall age- and sex-adjusted annual incidence rate over the 19-year study period was 2.3 (95% confidence interval [CI], 1.6-2.5) per 100,000 population aged 15 yr and older (women: 3.5 [95% CI, 2.3-3.9]; men: 1.0 [95% CI, 0.5-1.4]; p < 0.001). Using only the 1980 ACR criteria for SSc, the total annual-adjusted incidence rate was 1.2 (95% CI, 0.9-1.6) per 100,000 population aged 15 years and older (women: 1.8 [95% CI, 1.2-2.5]; men: 0.7 [95% CI, 0.3-1.2]; p < 0.001). The incidence increased significantly in individuals aged 45 years or older. The overall incidence rates of SSc increased over the length of the study (p for trend in the total incidence < 0.001). This was mainly due to a progressive increase of SSc in women between 1993 and 2002. By December 31, 2006, the overall age-adjusted SSc prevalence in the Lugo region of patients who met the criteria proposed by LeRoy and Medsger and/or the 1980 ACR criteria was 27.7 (95% CI, 21.1-35.84) per 100,000 population aged 15 years and older. Cardiopulmonary complications were the leading cause of death (13 of 20 cases). Compared with that in the general population, the probability of survival in patients with SSc was significantly reduced (p < 0.001).The current study establishes a baseline estimate of the incidence and clinical spectrum of SSc in northwestern Spain. According to our results, the incidence and prevalence of SSc in northwestern Spain are similar to those found in Greece and some regions of the United States. Our data confirm a reduced probability of survival in patients with SSc.

Entities:  

Mesh:

Year:  2008        PMID: 18794710     DOI: 10.1097/MD.0b013e318189372f

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  32 in total

1.  [Calcinosis and scleroderma].

Authors:  Xavier Pujol Olivares
Journal:  Aten Primaria       Date:  2018-10-26       Impact factor: 1.137

Review 2.  Pathophysiology and imaging of heart failure in women with autoimmune rheumatic diseases.

Authors:  Sophie I Mavrogeni; George Markousis-Mavrogenis; Loukia Koutsogeorgopoulou; Theodoros Dimitroulas; Vasiliki Vartela; Angelos Rigopoulos; Michel Noutsias; Genovefa Kolovou
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

3.  Sex disparities in systemic lupus erythematosus in Northwestern Spain are not due to ethnic diversity.

Authors:  Miguel A González-Gay; María D Alonso; Francisco Martínez-Vázquez; Javier Llorca
Journal:  Rheumatol Int       Date:  2014-09-12       Impact factor: 2.631

4.  Estimating the incidence of connective tissue diseases and vasculitides in a defined population in Northern Savo area in 2010.

Authors:  P Elfving; O Marjoniemi; H Niinisalo; A Kononoff; L Arstila; E Savolainen; J Rutanen; O Kaipiainen-Seppänen
Journal:  Rheumatol Int       Date:  2016-04-06       Impact factor: 2.631

5.  Social/economic costs and health-related quality of life in patients with rare diseases in Europe.

Authors:  Julio López-Bastida; Juan Oliva-Moreno; Renata Linertová; Pedro Serrano-Aguilar
Journal:  Eur J Health Econ       Date:  2016-03-29

Review 6.  MicroRNA-21 in Skin Fibrosis: Potential for Diagnosis and Treatment.

Authors:  Yan Li; Juan Zhang; Yuying Lei; Lechun Lyu; Ruiling Zuo; Ting Chen
Journal:  Mol Diagn Ther       Date:  2017-12       Impact factor: 4.074

Review 7.  Current developments in pediatric systemic sclerosis.

Authors:  Ivan Foeldvari
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

8.  The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study.

Authors:  Ada Man; Yanyan Zhu; Yuqing Zhang; Maureen Dubreuil; Young Hee Rho; Christine Peloquin; Robert W Simms; Hyon K Choi
Journal:  Ann Rheum Dis       Date:  2012-08-17       Impact factor: 19.103

Review 9.  The primary care physician in the early diagnosis of systemic sclerosis: the cornerstone of recognition and hope.

Authors:  Lesley Ann Saketkoo; Jeanette H Magnus; Mittie K Doyle
Journal:  Am J Med Sci       Date:  2014-01       Impact factor: 2.378

10.  Population-based analysis of hospitalizations for patients with systemic sclerosis in a West-European region over the period 2001-2012.

Authors:  Matteo Piga; Laura Casula; Silvia Sanna; Daniela Perra; Alberto Floris; Antonello Antonelli; Alberto Cauli; Alessandro Mathieu
Journal:  Rheumatol Int       Date:  2015-07-26       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.